PATENT CLAIM ANALYSIS

Application Number: 16269339
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "303000"]

Abstract:
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are (Z)-3-((2,6-dichloropyridin-4-yl)amino)-3-(((4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)methyl)amino)acrylonitrile and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.

Claim (Index 16):
The method of  claim 14 , wherein the eye condition is a retinopathy.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 99.0
- Lexical Diversity: 1.48148
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15316072', '13929451', '14436145', '10540371', '11890199']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8154635165244457
- 35 USC 102 Novelty (BERT): 0.5389000200347647
- Combined Prediction Score: 0.7878071668754777
- Mean Citation Score: 313.490862
- Max Citation Score: 390.1501
- Similarity Product: 206.23277596480847

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test